| Revenues |
42,730.6 |
8.5 |
| Profits |
9,915.0 |
13.3 |
| Assets |
50,011.1 |
-- |
| Stockholders' Equity |
18,369.8 |
-- |
| 1 | Johnson & Johnson | 112 | 53,324.0 | | 2 | Pfizer | 115 | 52,415.0 | | 3 | GlaxoSmithKline | 147 | 42,730.6 | | 4 | Novartis | 168 | 37,020.0 | | 5 | Sanofi-Aventis | 169 | 36,998.4 | | 6 | Roche Group | 188 | 34,702.8 | | 7 | AstraZeneca | 252 | 26,475.0 | | 8 | Merck | 308 | 22,636.0 | | 9 | Abbott Laboratories | 312 | 22,476.3 | | 10 | Wyeth | 346 | 20,350.7 | | 11 | Bristol-Myers Squibb | 406 | 17,914.0 | | 12 | Eli Lilly | 481 | 15,691.0 |
From the July 23, 2007 issue
Or is it the other way around? Fortune's David Kirkpatrick goes on the road to Beijing with Bill Gates, who threw his business model out the window. ( more)
Ex-CIA Intelligence Chief Jami Miscik was wrong about WMD in Iraq. But in her new career, Lehman brothers depends on her to say where it's safe to put billions. ( more)
|
| How the Countries Stack Up |
| Most profitable companies |
|
